146 related articles for article (PubMed ID: 20361090)
21. Recurrent refractory arterial thromboembolism associated with the Janus kinase 2 V617F mutation.
Ali FR; Roberts LN; Mistry H; Patel RK; Edmondson RA; Arya R
J Vasc Surg; 2009 Jan; 49(1):211-3. PubMed ID: 19174256
[TBL] [Abstract][Full Text] [Related]
22. Hypereosinophilia, JAK2V617F, and Budd-Chiari syndrome: who is responsible for what?
Mishchenko E; Tadmor T; Schiff E; Attias D; Polliack A
Am J Hematol; 2011 Feb; 86(2):223-4. PubMed ID: 21264914
[TBL] [Abstract][Full Text] [Related]
23. A novel subtype of myeloproliferative disorder? JAK2V617F-associated hypereosinophilia with hepatic venous thrombosis.
Dasari S; Naha K; Hande M; Vivek G
BMJ Case Rep; 2013 Aug; 2013():. PubMed ID: 23997080
[TBL] [Abstract][Full Text] [Related]
24. The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis.
Goulding C; Uttenthal B; Foroni L; Duke V; Traore A; Kottaridis P; Hoffbrand AV; Patch D; McNamara C
Int J Lab Hematol; 2008 Oct; 30(5):415-9. PubMed ID: 19046316
[TBL] [Abstract][Full Text] [Related]
25. Endothelial JAK2
Poisson J; Hilscher MB; Tanguy M; Hammoutene A; Boulanger CM; Villeval JL; Simonetto DA; Valla D; Shah VH; Rautou PE
J Hepatol; 2018 May; 68(5):1086-1087. PubMed ID: 29360553
[No Abstract] [Full Text] [Related]
26. JAK2 mutation: The best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis?
Janssen HL; Leebeek FW
Hepatology; 2006 Dec; 44(6):1391-3. PubMed ID: 17133464
[No Abstract] [Full Text] [Related]
27. JAK2 V617F: implications for thrombosis in myeloproliferative diseases.
Hexner EO
Curr Opin Hematol; 2007 Sep; 14(5):450-4. PubMed ID: 17934351
[TBL] [Abstract][Full Text] [Related]
28. Non conventional mutations associated with myeloproliferative disorders are absent in splanchnic venous thrombosis cases.
Jadli A; Kulkarni B; Ghosh K; Shetty S
Liver Int; 2012 Nov; 32(10):1596-7. PubMed ID: 22816981
[No Abstract] [Full Text] [Related]
29. Thrombotic risk factors in Chinese Budd-Chiari syndrome patients. An observational study with a systematic review of the literature.
Qi X; Wu F; Ren W; He C; Yin Z; Niu J; Bai M; Yang Z; Wu K; Fan D; Han G
Thromb Haemost; 2013 May; 109(5):878-84. PubMed ID: 23447059
[TBL] [Abstract][Full Text] [Related]
30. JAK2 V617F mutation and 46/1 haplotype in Chinese Budd-Chiari syndrome patients.
Wang H; Sun G; Zhang P; Zhang J; Gui E; Zu M; Jia E; Xu H; Xu L; Zhang J; Lu Z
J Gastroenterol Hepatol; 2014 Jan; 29(1):208-14. PubMed ID: 23980667
[TBL] [Abstract][Full Text] [Related]
31. [Budd-Chiari syndrome].
Plessier A
Rev Med Interne; 2013 Dec; 34(12):741-5. PubMed ID: 24262409
[TBL] [Abstract][Full Text] [Related]
32. [Budd-Chiari syndrome associated with chronic myeloproliferative syndromes: analysis of 6 cases].
Cobo F; Cervantes F; García-Pagán JC; Bosch J; Rozman C; Montserrat E
Med Clin (Barc); 1996 Nov; 107(17):660-3. PubMed ID: 9064408
[TBL] [Abstract][Full Text] [Related]
33. Low frequency of V617F mutation in JAK2 gene in Indian patients with hepatic venous outflow obstruction and extrahepatic portal venous obstruction.
Rai P; Kumar P; Mishra S; Aggarwal R
Indian J Gastroenterol; 2016 Sep; 35(5):366-371. PubMed ID: 27633031
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population.
Nielsen C; Birgens HS; Nordestgaard BG; Bojesen SE
Br J Haematol; 2013 Jan; 160(1):70-9. PubMed ID: 23116358
[TBL] [Abstract][Full Text] [Related]
35. JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects.
Benmoussa A; Dehbi H; Fehri S; Quessar A; Nadifi S
Pathol Biol (Paris); 2011 Aug; 59(4):e89-92. PubMed ID: 19939582
[TBL] [Abstract][Full Text] [Related]
36. Cardiac JAK2 mutation V617F in a patient with cardiomyopathy and myeloproliferative disease.
Gattenlohner S; Ertl G; Einsele H; Kircher S; Muller-Hermelink HK; Marx A
Ann Intern Med; 2008 Jul; 149(1):69-71. PubMed ID: 18591647
[No Abstract] [Full Text] [Related]
37. Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in Budd-Chiari syndrome and their impact on thrombotic complications post liver transplantation.
Westbrook RH; Lea NC; Mohamedali AM; Smith AE; Orr DW; Roberts LN; Heaton ND; Wendon JA; O'Grady JG; Heneghan MA; Mufti GJ
Liver Transpl; 2012 Jul; 18(7):819-27. PubMed ID: 22467227
[TBL] [Abstract][Full Text] [Related]
38. Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders.
Speletas M; Katodritou E; Daiou C; Mandala E; Papadakis E; Kioumi A; Ritis K; Korantzis I
Leuk Res; 2007 Aug; 31(8):1053-62. PubMed ID: 17045648
[TBL] [Abstract][Full Text] [Related]
39. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
Hussein K; Bock O; Kreipe H
Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
[TBL] [Abstract][Full Text] [Related]
40. Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR.
Waterhouse M; Follo M; Pfeifer D; von Bubnoff N; Duyster J; Bertz H; Finke J
Ann Hematol; 2016 Apr; 95(5):739-44. PubMed ID: 26931113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
